BioSpace News Archive

Shimadzu Medical Systems USA, a subsidiary of Shimadzu Corporation, is proud to announce the first U.S. installation of a Trinias SCORE Opera C12 (ceiling-mounted cutting edge angiography system) at Beaufort Memorial Hospital (Beaufort, SC).

Dermavant Sciences announced that the company has been named one of 2023’s Best Workplaces for Millennials™, Best Medium Workplaces™ and Best Workplaces in BioPharma™ by Fortune magazine and Great Place to Work® — Dermavant’s eighth recognition by the organizations.

InterVenn Biosciences, a life sciences company pioneering glycoproteomics, announced the publication of their discovery work in Advanced Adenoma and Colorectal Cancer early disease detection in the flagship journal of the American Gastroenterological Association, Gastroenterology.

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced new data from the Phase II FENopta study showing that investigational, oral fenebrutinib is brain penetrant and reduces brain lesions in people with relapsing multiple sclerosis (RMS), with a consistent safety profile to other fenebrutinib trials.

Positive results from a Phase 2b study showed that amlitelimab significantly improved signs and symptoms of moderate-to-severe atopic dermatitis in adults whose disease cannot be adequately controlled with topical medications or for whom topical medications are not a recommended treatment approach.

Geneseeq Technology Inc. announced on Thursday that Geneseeq’s Non-Small Cell Lung Cancer Tumor Mutational Burden Test Kit (Reversible terminator sequencing method) (NSCLC TMB Kit) has gained approval from the Chinese National Medical Products Administration (NMPA) on October 12, 2023 as a Breakthrough Medical Device.

Heidelberg Engineering, a global leader in ophthalmic imaging and healthcare data solutions, announces FDA clearance of its innovative all-in-one ANTERION® platform, designed to transform anterior segment diagnostics and streamline practice workflow.

Cidara Therapeutics, Inc. (Nasdaq: CDTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for rezafungin (rezafungin acetate) for the treatment of invasive candidiasis in adults.

Nona Biosciences and INGENIA Therapeutics announced that they have entered into a collaboration agreement.

Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced encouraging preliminary clinical data for RMC-6236, its RASMULTI(ON) Inhibitor, and RMC-6291, its RASG12C(ON) Inhibitor, from the respective Phase 1/1b studies.